Advertisement
U.S. Markets closed
S&P Futures
5,885.25 -11.00 (-0.19%) Dow Futures
43,119.00 -58.00 (-0.13%) Nasdaq Futures
20,460.25 -59.25 (-0.29%) Russell 2000 Futures
2,249.50 -6.00 (-0.27%) Crude Oil
70.30 -0.26 (-0.37%) Gold
2,743.80 +4.90 (+0.18%)
Takeda Pharmaceutical Company Limited (4502.T)
Tokyo - Tokyo Delayed Price. Currency in JPY
Follow
As of 11:35AM JST. Market open.
| Previous Close | 4,294.00 |
| Open | 4,270.00 |
| Bid | 4,247.00 x 0 |
| Ask | 4,250.00 x 0 |
| Day's Range | 4,232.00 - 4,272.00 |
| 52 Week Range | 3,852.00 - 4,494.00 |
| Volume | |
| Avg. Volume | 4,252,916 |
| Market Cap | 6.736T |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 45.19 |
| EPS (TTM) | 94.04 |
| Earnings Date | Oct 31, 2024 |
| Forward Dividend & Yield | 196.00 (4.56%) |
| Ex-Dividend Date | Mar 28, 2025 |
| 1y Target Est | 4,751.90 |
BenzingaAlumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis (PsO) and in Phase 2 trials for systemic lupus erythematosus (SLE). HC Wainwright analyst has initiated coverage on Alumis with a Buy rating and a price target of $30. Also Read: Newly-Lis
GuruFocus.comStrategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical
Insightful Portfolio Adjustments in Q3 2024 Highlight Growth Opportunities
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.